Novo Nordisk

Rank in 2013: 7th
Community Size: 12th
Activity: 10th
Engagement: 3rd
Virality: 13th

While Novo Nordisk ($NVO) did well engaging customers, its viral score in the Ogilvy study was ranked almost last, and its activity also lagged. Of course, the viral-ness problem could be attributed to a lack of anything catching on with consumers during the weeks in which Ogilvy reviewed its social media. Because otherwise, Novo seems progressive when it comes to social media. Its social media policy, for instance, seems progressive. It addresses social media directly on its website, giving it a separate heading, linking easily to all its social media sites, and introducing its open policy by saying, "We welcome conversations with all our stakeholders."

Novo also uses 9 of the 10 social media sites Ogilvy tracked, and actively networks and links across 8 of them. Its corporate Facebook page has 265,000 likes, although specifically states it is not intended for U.S. audiences. But check out its all-diabetes sponsored cycling team Facebook page Team Novo Nordisk: 1.2 million likes, and a direct link to its Instagram photos.

For more:
Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med
Novo heralds promising PhIII diabetes data for once-weekly semaglutide
Novo Nordisk backs out of a diabetes deal with Zosano
Novo Nordisk pulls Tresiba in Germany on pricing dispute
Novo Nordisk's diabetes combo beats Lantus in Phase III

Novo Nordisk

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.